New Developments in Myeloma, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 38-2 - March 1, 2024
- Latest edition
- Editor: Peter Leif Bergsagel
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 0 7 7 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 0 7 8 - 6
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of… Read more
Purchase options
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
- Contains 16 relevant, practice-oriented topics including molecular pathogenesis of multiple myeloma; monoclonal antibodies in the treatment of multiple myeloma; CAR-T cells in the treatment of multiple myeloma; management of newly diagnosed multiple myeloma today, and in the future; approach to high-risk multiple myeloma; new therapies on the horizon for relapsed refractory multiple myeloma; and more.
- Provides in-depth clinical reviews on new developments in myeloma, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Hematology, oncology
Molecular Pathogenesis of Multiple Myeloma: Clinical Implications
Immune-Pathogenesis of Myeloma
Smoldering Multiple Myeloma: Observation Versus Control Versus Cure
Cereblon-targeting ligase degraders in myeloma: Mechanisms of action and resistance
Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Bispecific Antibodies in the Treatment of Multiple Myeloma
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
Role of Consolidation and Maintenance
Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
Impact of Clonal Heterogeneity in Multiple Myeloma
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Approach to High-Risk Multiple Myeloma
New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications
Immune-Pathogenesis of Myeloma
Smoldering Multiple Myeloma: Observation Versus Control Versus Cure
Cereblon-targeting ligase degraders in myeloma: Mechanisms of action and resistance
Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Bispecific Antibodies in the Treatment of Multiple Myeloma
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
Role of Consolidation and Maintenance
Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
Impact of Clonal Heterogeneity in Multiple Myeloma
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Approach to High-Risk Multiple Myeloma
New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications
- Edition: 1
- Latest edition
- Volume: 38-2
- Published: March 1, 2024
- Language: English
PB
Peter Leif Bergsagel
Affiliations and expertise
Novel Therapeutics for Cancer Research, Director, Mayo Clinic SPORE in Multiple Myeloma, Co-Director, Hematologic Malignancies Program, Mayo Clinic Cancer Center, Consultant, Division of Hematology/Oncology, Professor of Medicine, Mayo Clinic College of Medicine